Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Medicis Pharmaceutical Corporation Q3 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions Let’s begin with Corey Davis with Natixis. Corey Davis – Natixis Thanks very much. Really just one question. That is in terms of your guidance for Q4, the reduction from your previous guidance in terms of revenue, is that coming from roll-forward effect...
- Earnings calls 2008-11-10
- Medicis' Accounting Error Puts Spotlight on Solodyn Weakness; Allergan Rejoices
- Medicis stock tumbled roughly 16 percent yesterday after it announced that it would restate six years of its numbers due to an accounting error. But the magnitude of the fall seems to have drawn attention not to the vanity pharma company's inability to count beans, but the...
- Blog posts 2008-09-25
- Medicis Solves One Solodyn Problem But Barr Pops Up With Another
- Barr Pharmaceuticals has filed to make a generic version of Medicis's acne drug, Solodyn. Medicis stock had received a nice boost at the beginning of December when it announced an unexpected deal with a different company, Impax, over generic versions of Solodyn. The deal meant Medicis would...
- Blog posts 2008-12-30
Additional Resources
- Solodyn, Remicade
- Solodyn (minocycline extended release tablets, Medicis) The Food and Drug Administration approved Solodyn minocycline extendedrelease tablets for treatment of inflammatory nonnodular moderate to severe acne vulgaris in patients 12 years of age and older. * Recommended Dosage: Prescribe 1 mg/kg daily for 12 weeks. Solodyn comes in...
- Research articles 2006-07-01
- Medicis Announces FDA Approval of SOLODYN and Medarex Announces Exercise of Option to Purchase Additional Shares.
- M2 PRESSWIRE-9 May 2006-US Financial Network: Medicis Announces FDA Approval of SOLODYN and Medarex Announces Exercise of Option to Purchase Additional SharesC1994-2006 M2 COMMUNICATIONS LTD RDATE:09052006 City of Industry, CA - Biotechnology industry alert provided by Equity IR News. Medarex, Inc....
- Research articles 2006-05-09
- Medicis' Solodyn Sales Stay Strong Despite Generic Challenges; Pay-to-Delay Works
- Despite both Teva and Sandoz dipping their generic toes into the Solodyn acne franchise, sales of Medicis' pimple-popper are still going up. Why? Because Medicis has paid most of those rivals to stop making their versions of the drug. by Jim Edwards
- Blog posts 2009-09-29
- Medicis Pharmaceutical Corporation Q1 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you, sir. Operator instructions Let's begin with James Kelly with Goldman Sachs. Sir, you may proceed. James Kelly – Goldman Sachs Great. Thank you very much. I will start with, you did mention on SOLODYN or you did mention in general that we didn't see any...
- Earnings calls 2008-05-30
- Medicis Doubled Pay of Exec Convicted of Off-Label Sales
- Medicis more than doubled the pay of its sales chief in 2008 even though that executive, Richard Havens, pled guilty to conspiracy to violate the Food and Drug Act last March. Havens, the former evp of sales, and three of his underlings pleaded guilty right before his April retirement to...
- Blog posts 2009-04-08
- The Allergan-Medicis Vanity Pharma Death Match Is About to Get Complicated
- Imagine your drug company has the following problems: A portfolio of expensive, discretionary cosmetic products that Medicare and Medicaid won't reimburse for; it's under investigation by the Department of Justice for alleged off-label promotion; the recession is crimping consumers' desire to spend money on non-essential drug products;...
- Blog posts 2008-09-08
- Q&A With Medicis CEO Jonah Shacknai, Who Sees a "Definite Downturn" in Vanity Pharma
- Medicis is going through a dramatic period. The vanity pharma company's Restylane dermal filler is in a battle royale with Allergan's Juvederm. It's waiting for FDA approval for Reloxin, its competitor to Allergan's Botox. And it just acquired LipoSonix, a high-intensity non-invasive ultrasound fat reducer. I talked...
- Blog posts 2008-10-06
- Medicis Employees Should Look Anxiously at Allergan Layoffs
- Sales reps at Restylane-maker Medicis should look anxiously at Allergan's announcement that its earnings and revenues are down. Allergan announced a "restructuring" to deal with the downturn -- that means 460 employees will get the ax, the company said. What does this have to do with Medicis?...
- Blog posts 2009-02-05
- Medicis Q1: One Day's Generic Competition Cost Company Up to 17% of Solodyn Sales
- Medicis revenues declined 23 percent to $100 million in Q1 2009, underlining how dependent the company is on the launch of its competitor to Botox. by Jim Edwards
- Blog posts 2009-05-11
- << Previous
- page 1 of 1
- Next >>
